EA202193178A1 - Способы лечения негативных симптомов шизофрении с помощью дейтерированного декстрометорфана и хинидина - Google Patents

Способы лечения негативных симптомов шизофрении с помощью дейтерированного декстрометорфана и хинидина

Info

Publication number
EA202193178A1
EA202193178A1 EA202193178A EA202193178A EA202193178A1 EA 202193178 A1 EA202193178 A1 EA 202193178A1 EA 202193178 A EA202193178 A EA 202193178A EA 202193178 A EA202193178 A EA 202193178A EA 202193178 A1 EA202193178 A1 EA 202193178A1
Authority
EA
Eurasian Patent Office
Prior art keywords
schizophrenia
methods
negative symptoms
treatment
quinidine
Prior art date
Application number
EA202193178A
Other languages
English (en)
Inventor
Санджай Дюбе
Original Assignee
Аванир Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Аванир Фармасьютикалз, Инк. filed Critical Аванир Фармасьютикалз, Инк.
Publication of EA202193178A1 publication Critical patent/EA202193178A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/49—Cinchonan derivatives, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение относится к способам лечения негативных симптомов шизофрении. Способы включают в себя введение пациенту, страдающему шизофренией, дейтерированного [d6]-декстрометорфана гидробромида в комбинации с хинидина сульфатом. Также раскрыты композиции, применимые для лечения негативных симптомов шизофрении.
EA202193178A 2019-03-18 2020-03-17 Способы лечения негативных симптомов шизофрении с помощью дейтерированного декстрометорфана и хинидина EA202193178A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962820142P 2019-03-18 2019-03-18
PCT/US2020/023205 WO2020190971A1 (en) 2019-03-18 2020-03-17 Methods of treating negative symptoms of schizophrenia using deuterated dextromethorphan and quinidine

Publications (1)

Publication Number Publication Date
EA202193178A1 true EA202193178A1 (ru) 2022-02-21

Family

ID=72519145

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202193178A EA202193178A1 (ru) 2019-03-18 2020-03-17 Способы лечения негативных симптомов шизофрении с помощью дейтерированного декстрометорфана и хинидина

Country Status (14)

Country Link
US (1) US20220071989A1 (ru)
EP (1) EP3941469A4 (ru)
JP (1) JP2022526101A (ru)
KR (1) KR20210153059A (ru)
CN (1) CN113825510A (ru)
AU (1) AU2020241611A1 (ru)
BR (1) BR112021018564A2 (ru)
CA (1) CA3134145A1 (ru)
EA (1) EA202193178A1 (ru)
IL (1) IL286386A (ru)
MX (1) MX2021011203A (ru)
SG (1) SG11202110150YA (ru)
TW (1) TW202102219A (ru)
WO (1) WO2020190971A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115322150B (zh) * 2021-05-11 2024-05-28 深圳信立泰药业股份有限公司 氘代右美沙芬氢溴酸盐的固体及其制备方法和医药用途
CN113209042A (zh) * 2021-05-28 2021-08-06 珠海润都制药股份有限公司 一种氢溴酸右美沙芬硫酸奎尼丁胶囊及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160361305A1 (en) * 2013-11-05 2016-12-15 Antecip Bioventures Ii Llc Compositions and methods comprising bupropion or related compounds for sustained delivery of dextromethorphan
EP3708168A3 (en) * 2014-09-14 2020-12-09 Avanir Pharmaceuticals, Inc. Combinations of deuterated dextromethorphan and quinidine for the treatment of agitation in dementia
WO2016109679A1 (en) * 2014-12-31 2016-07-07 Markovitz M D Ph D Paul Method of treating schizophrenia
WO2017117347A1 (en) * 2015-12-30 2017-07-06 Markovitz M D Paul Method of treating schizophrenia
EP3503879A4 (en) * 2016-08-26 2020-04-29 EXCIVA GmbH COMPOSITION AND METHOD FOR IT
EP3618819A4 (en) * 2017-05-04 2021-01-20 Exciva GmbH TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS AND PROCEDURES FOR IT

Also Published As

Publication number Publication date
IL286386A (en) 2021-10-31
CA3134145A1 (en) 2020-09-24
MX2021011203A (es) 2022-09-07
TW202102219A (zh) 2021-01-16
JP2022526101A (ja) 2022-05-23
BR112021018564A2 (pt) 2021-11-30
WO2020190971A1 (en) 2020-09-24
CN113825510A (zh) 2021-12-21
AU2020241611A1 (en) 2021-11-04
EP3941469A1 (en) 2022-01-26
SG11202110150YA (en) 2021-10-28
US20220071989A1 (en) 2022-03-10
KR20210153059A (ko) 2021-12-16
EP3941469A4 (en) 2022-05-18

Similar Documents

Publication Publication Date Title
EP3708168A3 (en) Combinations of deuterated dextromethorphan and quinidine for the treatment of agitation in dementia
PH12021550882A1 (en) Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders
MX2020009856A (es) Rimegepant para trastornos relacionados con el peptido relacionado con el gen para calcitonina (cgrp).
MA47313B1 (fr) Formulations sous-cutanées d'anticorps her2
EA200800007A1 (ru) Фармацевтические композиции на основе нейроактивного стероида и их применение
EA201490254A1 (ru) Комбинированное лечение гепатита с
EA201000603A1 (ru) ПРИМЕНЕНИЕ АНТИТЕЛ К TrkB ДЛЯ ЛЕЧЕНИЯ РЕСПИРАТОРНЫХ НАРУШЕНИЙ
JOP20200156A1 (ar) إيسكيتامين لعلاج الاكتئاب
EA202090510A1 (ru) Способ лечения бокового амиотрофического склероза придопидином
NO20063716L (no) Anvendelse av lavdose erytropoietin ved stimulering av endotel forloperceller, regenerering av organer og sinking av progresjonen av sluttorganskader
EA202092343A1 (ru) Лечение гнойного гидраденита с использованием ингибиторов jak
EA201391108A1 (ru) Лечение липодистрофии
MX2019009190A (es) Uso de gaboxadol en el tratamiento de tinnitus.
EA202193178A1 (ru) Способы лечения негативных симптомов шизофрении с помощью дейтерированного декстрометорфана и хинидина
BR112018067906A2 (pt) métodos de tratamento de depressão usando antagonistas do receptor de orexina-2
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
EP4324454A3 (en) Cross-linking agents and associated methods
MX2020008359A (es) Uso de ácido (1s,3s)-3-amino-4-(difluorometiliden) ciclopentano-1-carboxílico y ácido (s)-3-amino-4-(difluorometileni l)ciclopent-1-eno-1-carboxílico en el tratamiento del tinnitus, pérdida de audición neurosensorial aguda, enfermedad de meniere, síndrome de tourette, trastorno por déficit de atención e hiperactividad y adicción.
PH12021500006A1 (en) Methods of treatment and prevention of alzheimer's disease
EA202090242A1 (ru) Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов
ATE531366T1 (de) Zusammensetzungen und verfahren zur behandlung, verminderung, verbesserung oder linderung von erkrankungen des hinteren augensegments
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
MX2022001069A (es) Composiciones y metodos para el tratamiento de la presbicia.
CR20210514A (es) USO DE REBOXETINA PARA EL TRATAMIENTO DE NARCOLEPSIA (Divisional 2021-0183)
MY193963A (en) Composition for treating joint diseases and kit containing same